| Característica |
Objectiu de la convocatòria
The ADDF provides funding to academic centers and biotechs from around the world that are advancing therapeutic and biomarker development for Alzheimer's and related dementias. We have dedicated our funding to several key areas through 4 funding mechanisms:
Drug Development, Program to Accelerate Clinical Trials (PACT), Neuroimaging and CSF Biomarker Development, and Prevention Pipeline.
|
Característiques principals
FUNDING MECHANISMS:
Drug Development RFP: The Drug Development RFP seeks to support in vivo preclinical studies that advance lead molecules developed for Alzheimer’s disease and related dementias to IND-enabling studies. The proposed studies should be structured to deliver a compound with strong potential for clinical and commercial application.
Program to Accelerate Clinical Trials (PACT) RFP: The PACT RFP supports IND-enabling studies and early-phase clinical trials that test promising pharmacological interventions and devices for Alzheimer’s disease (AD) and related dementias. Both disease-modifying and symptomatic agents will be considered.
Neuroimaging and CSF Biomarker Development RFP: The aim of this RFP is to further develop and validate established biomarkers for which there is a clear clinical need in Alzheimer's disease and related dementias. This RFP prioritizes biomarkers with a defined context of use, a clear advantage over other relevant biomarkers, and a path to commercialization and/or clinical use.
Prevention Pipeline RFP: The ADDF seeks to support studies of cognitive symptoms due to health conditions, comparative effectiveness research, and epidemiological studies that probe whether the use or choice of drugs alters the risk for dementia or cognitive decline.
|
Lloc de presentació
El personal de l'IMIM i PSMAR que necessiteu més informació adreceu-vos a:
Servei de Recerca. C/ Doctor Aiguader, 88. 08003-Barcelona. Tel.: 93.316.05.76.
Marta López: mlopez4@imim.es Ext.: 1576
Carol Barnwell: cbarnwell@imim.es Ext.: 1670
|
Convocatòria (URL)
https://www.alzdiscovery.org/research-and-grants/funding-opportunities
|
Dotació
Drug development: up to $600,000
Program to accelerate clinical trials : up to $3 million
Neuroimaging and CSF biomarker development program: up to $600,000
Prevention pipeline: up to $3 million for clinical trials
|
Durada
Drug development: 1 year, potential for follow-up funding
Program to accelerate clinical trials : multi-year, potential for follow-up funding
Neuroimaging and CSF biomarker development program: 1 year, potential for follow-up funding. multi-year proposals can be considered
Prevention pipeline: multi-year, potential for follow-up funding
|
AVÍS IMPORTANT
Deadlines for 2021 RFPs:
LETTERS OF INTENT:
February 5,
May 28
October 1
INVITED FULL PROPOSALS:
April 16
July 30
December 3
|